'Game-changing' drug that slows incurable breast cancer approved for NHS

"Landmark Moment": UK Approves New Breast Cancer Drug

A new drug that helps slow the spread of an incurable type of breast cancer has been approved for use in Britain's state-run National Health Service, officials said on Friday. Scientists described the approval of capivasertib by the National Institute for Health and Care Excellence (NICE) as a "landmark moment". More than 1,000 women with the HR-positive HER2-negative type of the disease could benefit from taking the twice-daily pill every year,…

Pill that can slow breast cancer cleared for NHS use

AstraZeneca's oral drug Truqap will soon be available for people with advanced breast cancer via the NHS in England, as long as testing is available

New pill can slow incurable breast cancer - all you need to know in five minutes

A twice-a-day pill for the most common type of advanced breast cancer has been approved on the NHS in what scientists say is a “landmark moment”.Breast cancer is the most common form of cancer in the UK with one in seven women saying it has affected them in their lifetime.The new drug, capivasertib, has been shown in trials to slow the spread of the most common form of incurable breast cancer and is now available on the NHS following approval fr…

'Landmark moment' as breast cancer pill to be offered on NHS benefiting 'thousands of patients'

Thousands of women with advanced breast cancer in England and Wales are to be offered a "gamechanging" twice-a-day pill on the NHS after a U-turn by the medicines watchdog.The drug, capivasertib, also known as Truqap and manufactured by AstraZeneca, has been approved by the National Institute for Health and Care Excellence (Nice).As many as 3,000 women every year could benefit from the treatment for hormone receptor (HR)-positive HER2-negative b…

Breast cancer pill costing £77k each year rolled out on NHS

The new treatment will give hope to hundreds of women with few treatment options.

Breakthrough breast cancer drug approved for NHS

Capivasertib, which was developed in Britain, is the first drug of its kind and has been proven to double the time patients live without their tumours growing